LA JOLLA, California, Aug. 5 -- The University of California San Diego campus posted the following news:

* * *

Rebecsinib Clinical Trial Means New Options for Blood Cancer

*

Key Takeaways

* A clinical trial of rebecsinib, an experimental anti-cancer drug, is underway at UC San Diego for patients with two types of blood cancer.

* The investigational therapy holds potential for treating the more than 20 types of cance . . .

Click here for more information about our products